


**AMENDMENTS TO THE CLAIMS:**

Kindly cancel claims 1, 4 and 6-35, without prejudice, and add new claims 36-67, as shown below.

This listing of claims will replace all prior versions and listings of claims in the Application:

**Claims 1-35 (cancelled)**


**Claim 36 (new):** A compound having the formula:



**Ia**


wherein:

R<sub>1</sub> represents a radical selected from the group consisting of



, -NR<sub>5</sub>R<sub>6</sub>, -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>, hydroxyalkyl, hydroxyalkoxy, polyhydroxyalkyl,

alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, R<sub>9</sub>, -OR<sub>9</sub>,



; n being an integer from 1 to 4;

R<sub>2</sub> and R<sub>3</sub> are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R<sub>4</sub> is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and -NR<sub>12</sub>R<sub>13</sub>;

R<sub>5</sub> and R<sub>7</sub> are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R<sub>9</sub>, -(C=O)R<sub>14</sub> and -(C=O)R<sub>9</sub>;

R<sub>6</sub>, R<sub>8</sub>, R<sub>12</sub>, and R<sub>13</sub> are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R<sub>9</sub>, -(C=O)R<sub>15</sub> and -(C=O)R<sub>9</sub>;

or R<sub>5</sub> and R<sub>6</sub> taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R<sub>7</sub> and R<sub>8</sub> taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;

R<sub>9</sub> is a radical of the formula -W-O(C=O)-CH<sub>3</sub>, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;

R<sub>10</sub> and R<sub>11</sub> are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R<sub>14</sub> is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

R<sub>15</sub> is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group, and pharmaceutically acceptable salts of said compound.

**Claim 37 (new):** A compound according to claim 36, selected from the group consisting of:

2,2'-[[3-(2,2,2-Trifluoroethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(4-Morpholinyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(1-Piperidiny)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(4-Morpholinylsulfonyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(Methoxyethoxy)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[[3-Bis(phenylmethyl)amino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[1-(4-Methylpiperazinyl)methyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(Diethylaminomethyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(Dimethylaminomethyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[4-(Morpholinyl)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Hydroxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[2-(1,1-Dioxide-2,3,4,5-tetrahydro)isothiazolyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(3-Hydroxypropyl)-N-ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(2-Hydroxyethyl)-N-ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[1-(4-Hydroxypiperidiny)]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(3-Hydroxypropyl)-N-methylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Acetoxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(2-Hydroxyethyl)-N-methylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Hydroxybutyl)-N-methylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]]phenol;


2,2'-[[3-[N-(2-Hydroxyethyl)-N-propylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]]phenol;

2,2'-[[3-[N-(4-Hydroxybutyl)-N-propylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]]phenol;

2,2'-[[3-[N-(6-Hydroxyhexyl)-N-ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]]phenol; and

2,2'-[[3-[N-(5-Hydroxypentyl)-N-ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]]phenol.


**Claim 38 (new):** The compound according to claim 36 having the formula:



**Claim 39 (new):** The compound according to claim 36 having the formula:

HAYES SOLOWAY P.C.  
3450 E. SUNRISE DRIVE,  
SUITE 140  
TUCSON, AZ 85718  
TEL. 520.882.7623  
FAX. 520.882.7643

175 CANAL STREET  
MANCHESTER, NH 03101  
TEL. 603.668.1400  
FAX. 603.668.8567



**Claim 40 (new):** The compound according to claim 36 having the name 2,2'-[[3-[N-(4-Hydroxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**Claim 41 (new):** The compound according to claim 36 having the name 2,2'-[[3-[N-(2-Hydroxyethyl)-N-methylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**Claim 42 (new):** The compound according to claim 36 having the name 2,2'-[[3-[N-(2-Hydroxyethyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

**Claim 43 (new):** A pharmaceutical composition for treating or preventing pneumovirus infection, said composition comprising a compound according to claim 36 in an amount effective to attenuate infectivity of said virus, and a pharmaceutically acceptable carrier medium.

**Claim 44 (new):** A pharmaceutical composition according to claim 43, further comprising at least one supplemental active agent selected from the group consisting of interferon, ribavirin and an immunomodulator, an immunoglobulin, an anti-inflammatory agent, an antibiotic, an anti-viral and an anti-infective.

**Claim 45 (new):** A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises ethanol.

**Claim 46 (new):** A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises propylene glycol.

**Claim 47 (new):** A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises water.

**Claim 48 (new):** A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 50% ethanol.

**Claim 49 (new):** A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 60% ethanol.

**Claim 50 (new):** A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 70% ethanol.

**Claim 51 (new):** A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 80% ethanol.

**Claim 52 (new):** A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 90% ethanol.

**Claim 53 (new):** A pharmaceutical composition according to claim 52, wherein said pharmaceutically composition comprises less than 5% water.

**Claim 54 (new):** A pharmaceutical composition according to claim 45, wherein said pharmaceutically acceptable carrier medium comprises ethanol, water, and propylene glycol.

**Claim 55 (new):** A pharmaceutical composition according to claim 54, wherein said pharmaceutically composition comprises about 85% ethanol, about 10% propylene glycol, and about 5% water.

**Claim 56 (new):** A method of treatment of pneumovirus infection in a patient in need of said treatment, said method comprising administering to said patient a therapeutically effective amount of a compound according to claim 36.

**Claim 57 (new):** A method as claimed in claim 56, wherein said compound is administered through inhalation or intrication.

**Claim 58 (new):** A method as claimed in claim 56, wherein said compound is administered by an electrohydrodynamic delivery device.

**Claim 59 (new):** A method as claimed in claim 56, wherein said electrohydrodynamic delivery device is hand-held.

**Claim 60 (new):** A method as claimed in claim 58, wherein said electrohydrodynamic delivery device is disposable.

**Claim 61 (new):** A method as claimed in claim 58, wherein said electrohydrodynamic delivery device is for a single user.

**Claim 62 (new):** A method as claimed in claim 58, wherein said electrohydrodynamic delivery device comprises a removable mouthpiece.


**Claim 63 (new):** A method as claimed in claim 58, wherein said electrohydrodynamic delivery device comprises a mask.



**Claim 64 (new):** A method of treating cells in culture that are susceptible to infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said cultures an effective amount of a compound according to claim 36.


**Claim 65 (new):** A method of treating biological materials that are susceptible to infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said materials an effective amount of a compound according to claim 36.


**Claim 66 (new):** A compound having the formula:



wherein:

$R_1'$  represents a radical selected from the group consisting of





R<sub>2</sub> and R<sub>3</sub> are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R<sub>4</sub> is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and -NR<sub>12</sub>R<sub>13</sub>;

R<sub>5</sub> and R<sub>7</sub> are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R<sub>9</sub>, -(C=O)R<sub>14</sub> and -(C=O)R<sub>9</sub>;

R<sub>6</sub>, R<sub>8</sub>, R<sub>12</sub>, and R<sub>13</sub> are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R<sub>9</sub>, -(C=O)R<sub>15</sub> and -(C=O)R<sub>9</sub>;

or R<sub>5</sub> and R<sub>6</sub> taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R<sub>7</sub> and R<sub>8</sub> taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;


R<sub>9</sub> is a radical of the formula -W-O(C=O)-CH<sub>3</sub>, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;

R<sub>10</sub> and R<sub>11</sub> are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;


R<sub>14</sub> is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

R<sub>15</sub> is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group, and pharmaceutically acceptable salts of said compound.

**Claim 67 (new):** A compound having the formula:





wherein R<sub>b</sub> is selected from the group consisting of -CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>, -

CH(CH<sub>3</sub>) OCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>-OCH<sub>2</sub>CH<sub>2</sub>-OCH<sub>3</sub>, , -CH<sub>2</sub>-OCH<sub>2</sub>CH<sub>2</sub>-Si(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, -(CH<sub>2</sub>)<sub>2</sub>Si(CH<sub>3</sub>)<sub>3</sub>, -CON(R<sub>c</sub>R<sub>d</sub>)<sub>2</sub>, -CSN(R<sub>c</sub>R<sub>d</sub>)<sub>2</sub>, and -PO(NR<sub>c</sub>R<sub>d</sub>)<sub>2</sub>;

R<sub>c</sub> and R<sub>d</sub> are independently selected from an alkyl group;

R<sub>1</sub>" represents a radical selected from the group consisting of



R<sub>2</sub> and R<sub>3</sub> are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R<sub>4</sub> is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and -NR<sub>12</sub>R<sub>13</sub>;

R<sub>5</sub> and R<sub>7</sub> are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R<sub>9</sub>, -(C=O)R<sub>14</sub> and -(C=O)R<sub>9</sub>;

R<sub>6</sub>, R<sub>8</sub>, R<sub>12</sub>, and R<sub>13</sub> are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R<sub>9</sub>, -(C=O)R<sub>15</sub> and -(C=O)R<sub>9</sub>;

or R<sub>5</sub> and R<sub>6</sub> taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R<sub>7</sub> and R<sub>8</sub> taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing

one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;


R<sub>9</sub> is a radical of the formula -W-O(C=O)-CH<sub>3</sub>, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;

R<sub>10</sub> and R<sub>11</sub> are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R<sub>14</sub> is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

R<sub>15</sub> is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

P is a protected formaldehyde group selected from the group consisting of



wherein R<sub>16</sub>, R<sub>17</sub>, R<sub>18</sub> and R<sub>19</sub> are independently selected from the group consisting of hydrogen and alkyl; and pharmaceutically acceptable salts of said compound.